Spnib 70mg Tablet (Dasatinib)

Spnib 70mg Tablet is a prescription medicine containing Dasatinib. It is supplied in a 70mg tablet presentation and belongs to the bcr::abl1 and src-family tyrosine kinase inhibitor class. It should be used only under the supervision of a clinician experienced in the relevant disease area.
Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase in adults. Chronic, accelerated, myeloid blast or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
Dasatinib 70mg tablet inhibits BCR::ABL1 and SRC-family kinases as well as several other kinases. Blocking the abnormal BCR::ABL1 signalling protein suppresses proliferation and survival of Philadelphia chromosome-positive leukemic cells. It is a targeted TKI rather than conventional cytotoxic chemotherapy. The 70mg strength describes the commercial presentation; it does not automatically represent the complete prescribed dose. Dose and duration depend on diagnosis, treatment protocol, organ function, concomitant medicines and treatment tolerance.

• Spnib 60mg may be prescribed in the following established clinical settings. The exact treatment line, combination regimen and duration depend on the diagnosis, current labeling and specialist assessment.
  
• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase in adults.
  
• Chronic, accelerated, myeloid blast or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib tablet.
  
• Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy in adults; pediatric indications also exist under current labeling.
  

Dasatinib 70mg tablet inhibits BCR::ABL1 and SRC-family kinases as well as several other kinases. Blocking the abnormal BCR::ABL1 signalling protein suppresses proliferation and survival of Philadelphia chromosome-positive leukemic cells. It is a targeted TKI rather than conventional cytotoxic chemotherapy.

• Clinical evidence in this section relates to the Dasatinib 70mg molecule and relevant treatment regimens; it should not be interpreted as evidence that every pivotal trial specifically studied the Spnib tablet commercial presentation.
  
• Randomized and long-term studies established dasatinib tablet as an effective TKI in newly diagnosed chronic-phase Ph+ CML and in patients resistant or intolerant to prior therapy.
  
• Molecular monitoring of BCR::ABL1 is central to assessing depth and durability of response.
  
• Clinical evidence is molecule-level and should not be presented as a Spnib 70mg-specific clinical trial unless brand-specific evidence exists.
  

The side effects of Dasatinib 70mg vary by indication, dose, treatment duration, concomitant medicines and individual patient factors. Common or clinically relevant effects include:

• Myelosuppression
  
• Fluid retention
  
• Pleural effusion
  
• Diarrhea
  
• Headache
  
• Rash
  
• Musculoskeletal pain
  
• Bleeding

Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.

The dose of Spnib 70mg tablet depends on the indication and clinical setting. The 70mg presentation should not be confused with the total prescribed daily dose.

These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications and supportive medicines.

If a dose of Spnib 70mg tablet is missed, follow the current patient leaflet and the treating team's instructions. Do not automatically double the next dose. If vomiting occurs after an oral dose, do not repeat the dose unless specifically instructed.

Monitoring is individualized according to the disease and treatment regimen. It may include:

• CBC
  
• BCR::ABL1 molecular response
  
• Pleural effusion/fluid retention
  
• Blood pressure and cardiovascular symptoms
  
• ECG/electrolytes when indicated
  
• Pulmonary hypertension symptoms
  
• Liver function as clinically indicated
  
  

1. DailyMed. Dasatinib Tablets prescribing information, updated May 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eed6b7b-a09d-4d2e-a345-968dd68323bc​
2. Current CML/Ph+ ALL treatment guidelines https://pmc.ncbi.nlm.nih.gov/articles/PMC7386894/​
3. Current India-specific Spnib package insert before publication https://hivhub.in/shop/spnib-70mg-tablet/?srsltid=AU7gw4XR46IPfH5AR4e9YgheywjBOd9CljDhc_Z629x23sJdTPM3egVK​
4.European LeukemiaNet. 2025 European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia https://www.nature.com/articles/s41375-025-02664-w​
5. U.S. Food and Drug Administration. SPRYCEL (dasatinib) Tablets Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf​